Ranchi News Desk

Gastroparesis Market is anticipated to record a valuation of US$6,025.11 Million by 2027, a recent study by The Insight Partners

 Breaking News
  • No posts were found

Gastroparesis Market is anticipated to record a valuation of US$6,025.11 Million by 2027, a recent study by The Insight Partners

November 19
21:00 2021
Gastroparesis Market is anticipated to record a valuation of US$6,025.11 Million by 2027, a recent study by The Insight Partners
theinsightpartners
The idiopathic type held the largest share of the market in 2019; however, the market for the diabetic type is estimated to grow at the highest CAGR during the forecast period.

According to our new research study on “Gastroparesis Market Forecast to 2027 – COVID-19 Impact and Analysis – by Type, Drug Class Type, and Distribution Channel,” the market is expected to reach US$ 6,025.11 million by 2027 from US$ 4,338.61 million in 2019; it is estimated to grow at a CAGR of 4.3% from 2020 to 2027. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth. The market growth is primarily attributed to the increasing diabetes prevalence and growing geriatric population. However, side-effects of gastroparesis drugs restrain the growth of the market.

Strategic Insights:

Report Coverage             

Details

Market Size Value in      

(US$ 4,338.61 million in 2019)

Market Size Value by    

(US$ 6,025.11 million by 2027)

Growth Rate     

(CAGR of 4.3% from 2020 to 2027)

Forecast Period

(2020- 2028)

Base Year           

(2020)

No. of Pages     

(155)

No. Tables          

(68)

Segments covered         

(By Gastroparesis Type; Drug Class Type and Distribution Channel)

Regional scope 

(North America; Europe; Asia Pacific; Latin America; MEA)

Country scope  

(US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina)

Report coverage             

(Revenue forecast, company ranking, competitive landscape, growth factors, and trends)

Get Sample PDF Copy of Gastroparesis Market at: https://www.theinsightpartners.com/sample/TIPRE00008992/

Gastroparesis is a medical condition characterized by the disability of stomach to empty itself of food in the usual way. Damaged nerves such as vagus nerves and muscles associated with gastric motility may also lead to gastroparesis. The condition is commonly observed in diabetic people. Gastroparesis can be classified as diabetic, idiopathic, and post-surgical on the basis of the cause. Apart from these, viral infections, nerve-related diseases, excessive narcotics and several antidepressant consumption, and amyloidosis may also lead to the onset of gastroparesis.

Increasing Geriatric Population Accelerating Demand for Gastroparesis Treatment Modalities

Gastric emptying is associated with the coordination among the motor activity of proximal stomach, distal stomach, and duodenum. These internal organs are controlled by the feedback mechanism from neural signals generated through the interaction between nutrients and small intestine. Aging leads to diminished homeostatic regulations of physiologic functions, along with the slowing of gastric emptying. Moreover, it influences motor and sensory functions. In addition, geriatric population is highly vulnerable to gastroparesis due to factors such as the poor oral medication absorption, inadequate appetite regulation, and postprandial glycemia. According to the 2019 revision of World Population Prospects, 1 in 6 people would be aged more than 65 by 2050, with an increase from 1 in 11 in 2019. Furthermore, according to the same study, one in four people in Europe and North America is projected to be aged over 65 by 2050. Also, the number of people with age more than 80 would reach 426 million by 2050 from 143 million in 2019. Thus, the continuous increase in aging population, coupled with the rise in issues associated with gastric emptying among these populations, drives the gastroparesis market growth.

The COVID-19 pandemic has disrupted supply chain of over-the-counter (OTC) and prescription drugs, and this is likely to limit the market growth in the next few quarters. Moreover, the emphasis of health care providers and medical industries on COVID-19 has led to the lowered focus on the diagnosis and treatment for gastroparesis, which is limiting the market growth to a certain extent.

Download the Latest COVID-19 Analysis on Gastroparesis Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00008992

On the basis of type, the gastroparesis market is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019, while the diabetic segment is estimated to register the highest CAGR during the forecast period.

The gastroparesis market, based on drug class type, is segmented into prokinetic agents, antiemetic agents, and botulinum toxin injections. The prokinetic agents segment held the largest market share in 2019 and is estimated to register the highest CAGR during 2020–2027.

On the basis of distribution channel, the gastroparesis market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019, and the market for the same is estimated to grow at the highest CAGR from 2020 to 2027.

Gastroparesis Market: Competitive Landscape and Key Developments

EVOKE PHARMA, Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.), Johnson And Johnson Services, Inc., Allergan Plc, NEUROGASTRX, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD, Pfizer Inc., ANI Pharmaceuticals, Inc., Ipca Laboratories Ltd., and Cinrx Pharma, LLC (Cindome Pharma) are among the leading companies operating in the gastroparesis market.

Order a Copy of Gastroparesis Market Shares, Strategies and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00008992/

Browse Related Reports and get Sample copy

Gastroparesis Drugs for Medical Implants Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Drug Class (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injections); Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, Others); End User (Hospitals, Pharmacies, Clinics, E-commerce) and Geography

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/pr/gastroparesis-market

Related Articles